Prolonged survival with the early use of a novel extracorporeal photopheresis regimen in patients with Sezary syndrome
Crystal Gao, Christopher McCormack, Carrie van der Weyden, Michelle S Goh, Belinda A Campbell, Robert Twigger, Odette Buelens, Simon J Harrison, Christine Khoo, Stephen Lade, H Miles Prince
Blood | AMER SOC HEMATOLOGY | Published : 2019
Extracorporeal photopheresis (ECP) has demonstrated therapeutic benefit in patients with Sézary syndrome (SS) and erythrodermic mycosis fungoides (e-MF). To examine the efficacy of ECP in the modern era of novel therapies, we conducted a retrospective analysis of 65 patients with a diagnosis of SS or e-MF with blood involvement who were treated with ECP at our institute. Overall survival (OS), time to next treatment (TTNT), and skin response rate (RR) were used as the study end points to determine patient outcome. The median follow-up from diagnosis was 48 months (range 1-225 months), with a median predicted OS of 120 months. The majority (88%) of patients commenced ECP at treatment lines 1 ..View full abstract
The authors thank the Monash University Medical School for their support.